Anaheim Bio

€40.0M Series A

Announced: Nov 5, 2026
Sector: Biotechnology
Investors: 6

Summary

Anaheim Bio launched with €40 million in Series A financing to advance its CPPD treatment into clinical development. Anaheim Bio is a developer of treatments for calcium pyrophosphate deposition disease.

Investors

Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest, Thuja Capital